UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

Annals of oncology, 2016-08, Vol.27 (8), p.1449-1455

2016

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4292-4302

2002

Volltextzugriff (PDF)

Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers

Cancer treatment reviews, 2010-11, Vol.36 (7), p.566-575

2010

Volltextzugriff (PDF)

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Annals of oncology, 2013-03, Vol.24 (3), p.679-687

2013

Volltextzugriff (PDF)

Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)

Gynecologic oncology, 2012-04, Vol.125 (1), p.31-36

2012

Volltextzugriff (PDF)

Prognostic factors in ovarian cancer: how close are we to a complete picture?

Annals of oncology, 2005-01, Vol.16 (1), p.4-6

2005

Volltextzugriff (PDF)

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis

Gynecologic oncology, 2015-04, Vol.137, p.8-9

2015

Volltextzugriff (PDF)

A decade of clinical development of PARP inhibitors in perspective

Annals of oncology, 2019-09, Vol.30 (9), p.1437-1447

2019

Volltextzugriff (PDF)

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer

European journal of obstetrics & gynecology and reproductive biology, 2008-05, Vol.138 (1), p.71-75

2008

Volltextzugriff (PDF)

55IN - Targeting DNA Repair Deficiency in Ovarian and Endometrial Cancers

Annals of oncology, 2012-09, Vol.23, p.ix40-ix40

Kaye, S.B.

2012

Volltextzugriff (PDF)

Targeting DNA Repair Deficiency in Ovarian and Endometrial Cancers

Annals of oncology, 2012-09, Vol.23, p.ix40

Kaye, S.B.

2012

Volltextzugriff (PDF)

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

Gynecologic oncology, 2008-04, Vol.109 (1), p.27-32

2008

Volltextzugriff (PDF)

Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i1-i3

Kaye, S B

2016

Volltextzugriff (PDF)

A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma

Annals of oncology, 2009-11, Vol.20 (11), p.1787-1793

2009

Volltextzugriff (PDF)

Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival

Journal of clinical oncology, 2000-01, Vol.18 (1), p.87-93

2000

Volltextzugriff (PDF)

New developments in the treatment of ovarian cancer--future perspectives

Annals of oncology, 2013-12, Vol.24 Suppl 10 (Suppl 10), p.x69-x76

2013

Volltextzugriff (PDF)

The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure

American journal of transplantation, 2017-01, Vol.17 (1), p.210-217

2017

Volltextzugriff (PDF)

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Annals of oncology, 2014-10, Vol.25 (10), p.1988-1995

2014

Volltextzugriff (PDF)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Annals of oncology, 2011-01, Vol.22 (1), p.39-48

2011

Volltextzugriff (PDF)

Capsular distention syndrome: sine anterior chamber shallowing?

Canadian journal of ophthalmology, 2009, Vol.44 (5), p.e45-e45

2009

Volltextzugriff (PDF)

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Annals of oncology, 2013-01, Vol.24 (1), p.145-152

2013

Volltextzugriff (PDF)

Epstein-Barr virus (types 1 and 2) in the tear film in Sjogren's syndrome and HIV infection

Journal of medical virology, 2002-11, Vol.68 (3), p.378-383

2002

Volltextzugriff (PDF)

Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients

Annals of oncology, 2013-11, Vol.24 (11), p.2813-2818

2013

Volltextzugriff (PDF)

Management of malignant teratoma: does referral to a specialist unit matter?

The Lancet (British edition), 1993-04, Vol.341 (8851), p.999-1002

1993

Volltextzugriff (PDF)

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

Annals of oncology, 2008-05, Vol.19 (5), p.898-902

2008

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Englisch
(190)

Erscheinungsjahr

n.n

Thema

Humans
(111)
Science & Technology
(93)
Life Sciences & Biomedicine
(92)
Female
(75)
Oncology
(75)
Biological And Medical Sciences
(65)
Medical Sciences
(65)
Middle Aged
(54)
Adult
(46)
Aged
(46)
Male
(42)
Pharmacology. Drug Treatments
(41)
Antineoplastic Agents
(37)
Ovarian Neoplasms - Drug Therapy
(29)
Tumors
(27)
Chemotherapy
(26)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Ovarian Cancer
(21)
Gynecology. Andrology. Obstetrics
(20)
Prognosis
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC)

Prognostic factors in ovarian cancer: how close are we to a complete picture?

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis

A decade of clinical development of PARP inhibitors in perspective

Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer

55IN - Targeting DNA Repair Deficiency in Ovarian and Endometrial Cancers

Targeting DNA Repair Deficiency in Ovarian and Endometrial Cancers

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years

A feasibility study of sequential doublet chemotherapy comprising carboplatin–doxorubicin and carboplatin–paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma

Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival

New developments in the treatment of ovarian cancer--future perspectives

The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Capsular distention syndrome: sine anterior chamber shallowing?

A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer

Epstein-Barr virus (types 1 and 2) in the tear film in Sjogren's syndrome and HIV infection

Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients

Management of malignant teratoma: does referral to a specialist unit matter?

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

Suchergebnisse filtern